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Abstract
Background
Salmonella serovars Typhi (S. Typhi) and Paratyphi A (S. Paratyphi A), the causative agents
of enteric fever, have been routinely isolated organisms from the blood of febrile patients in
the Kathmandu Valley since the early 1990s. Susceptibility against commonly used antimi-
crobials for treating enteric fever has gradually changed throughout South Asia since this
time, posing serious treatment challenges. Here, we aimed to longitudinally describe trends
in the isolation of Salmonella enterica and assess changes in their antimicrobial susceptibil-
ity in Kathmandu over a 23-year period.
Methods
We conducted a retrospective analysis of standardised microbiological data from April 1992
to December 2014 at a single healthcare facility in Kathmandu, examining time trends of
Salmonella-associated bacteraemia and the corresponding antimicrobial susceptibility pro-
files of the isolated organisms.
Results
Over 23 years there were 30,353 positive blood cultures. Salmonella enterica accounted for
65.4% (19,857/30,353) of all the bacteria positive blood cultures. S. Typhi and S. Paratyphi
A were the dominant serovars, constituting 68.5% (13,592/19,857) and 30.5% (6,057/
19,857) of all isolated Salmonellae. We observed (i) a peak in the number of Salmonella-
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positive cultures in 2002, a year of heavy rainfall and flooding in the Kathmandu Valley, fol-
lowed by a decline toward pre-flood baseline by 2014, (ii) an increase in the proportion of S.
Paratyphi in all Salmonella-positive cultures between 1992 and 2014, (iii) a decrease in the
prevalence of MDR for both S. Typhi and S. Paratyphi, and (iv) a recent increase in fluoro-
quinolone non-susceptibility in both S. Typhi and S. Paratyphi isolates.
Conclusions
Our work describes significant changes in the epidemiology of Salmonella enterica in the
Kathmandu Valley during the last quarter of a century. We highlight the need to examine
current treatment protocols for enteric fever and suggest a change from fluoroquinolone
monotherapy to combination therapies of macrolides or cephalosporins along with older
first-line antimicrobials that have regained their efficacy.
Author summary
Aiming to understand the epidemiology and changing patterns of the Salmonella enterica
serovars Typhi and Paratyphi A within a single healthcare facility in Kathmandu, we ret-
rospectively analysed 23 years of microbiological blood culture data. From 224,741 blood
cultures performed, 30,353 were confirmed to be positive for pathogenic bacteria, of
which Salmonella enterica accounted for 65.4% (19,857/30,353) of all the bacteria positive
blood cultures. S. Typhi and S. Paratyphi A were the dominant serovars, constituting
68.5% (13,592/19,857) and 30.5% (6,057/19,857) of all isolated Salmonellae. We observed
that S. Typhi and S. Paratyphi A remained the leading cause of bacterial febrile illness
since the 1990s. Additionally, antimicrobial resistance is a major public health challenge,
and resistance against the antimicrobials most commonly used for treating enteric fever
has developed over the last two decades. In this analysis we were able to document a
decrease in the number of Salmonella-positive cultures from 2002 to 2014 and an increase
in the proportion of S. Paratyphi A in all Salmonella-positive cultures between 1992 and
2014. Concurrently, we also observed a decrease in MDR for S. Typhi and S. Paratyphi
and a recent increase in fluoroquinolone non-susceptibility in both serovars.
Introduction
Enteric (typhoid) fever is a systemic disease caused by Salmonella serovars Typhi (S. Typhi)
and Paratyphi A (S. Paratyphi A). Global estimates suggest that 12 to 27 million new cases of
enteric fever occur annually resulting in 130,000 to 220,000 deaths, which predominantly
occur in low-middle income countries (LMICs) [1–3]. Enteric fever has been a public health
concern in Nepal for some time, with S. Typhi and S. Paratyphi A consistently being regularly
isolated from the blood of febrile patients in the Kathmandu Valley since the early 1990s [4–6].
The sustained high prevalence of S. Typhi and S. Paratyphi A in the Kathmandu Valley has
been attributed to a contaminated water supply and poor sanitation [6].
Enteric fever is an infection that requires antimicrobial therapy, but antimicrobial resis-
tance (AMR) hinders effective treatment, prolonging the duration of fever and leaving patients
at risk of further complications. As a consequence of horizontal acquisition of resistance genes
and point mutations, the antimicrobial susceptibility profiles of S. Typhi and S. Paratyphi A
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have changed substantially in Asia over the past 30 years. Organisms resistant to ampicillin,
chloramphenicol, and co-trimoxazole (multidrug-resistant, MDR) first appeared in the 1980s
and 1990s and were associated with large focal outbreaks [7]. The emergence and persistence of
resistance against these antimicrobials diverted clinical practice towards more frequent use of
fluoroquinolones to treat enteric fever [8]. This shift towards the use of fluoroquinolones was
predictably followed by a general decline in susceptibility against these antimicrobials through
sequential mutations in the genes encoding the enzymes targeted by fluoroquinolones [8].
Understanding longitudinal changes in isolation patterns of Salmonella serovars and fluctu-
ations in their corresponding antimicrobial susceptibility profiles in locations where enteric
fever is endemic is important for disease surveillance. These data are critical for improving
clinical care, updating treatment guidelines, and guiding public health interventions. Aiming
to delineate trends in the isolation of invasive Salmonella and their corresponding antimicro-
bial susceptibility profiles, we conducted a retrospective analysis of 23 years of Salmonella iso-
lated from blood cultures taken from patients attending a major healthcare facility in the
Kathmandu Valley in Nepal.
Material and methods
Ethics statement
Data for this study consisted of anonymised laboratory results devoid of individual patient
information or identifiers. This study was therefore part of the routine surveillance measures
within this healthcare facility and ethical approval and individual informed consent were not
necessary. However, a written permission, for access and analysis of the data, was sought and
obtained from the Patan Hospital management.
Study design and data collection
This study was a retrospective analysis of all blood cultures performed between April 1992 and
December 2014 at Patan Hospital. Patan Hospital is located in Lalitpur Sub-metropolitan City
(LSMC) within the Kathmandu Valley in central Nepal. It is one of three general hospitals in
the greater metropolitan area of Kathmandu. The hospital had a capacity of 138 beds in 1992,
350 beds in 2014, a current capacity of 592 beds, and provides emergency and elective services
to outpatients (approximately 200,000 outpatient visits per year) and inpatients, 90% of which
live in LSMC.
For each patient, the date of blood draw, the ward in which the blood sample was taken, the
result of the culture (whether positive or negative) and the susceptibility of the isolate to com-
monly used antimicrobials were recorded by a member of the hospital laboratory personnel.
For the purposes of this investigation, all handwritten data recorded between the specified
dates were transcribed into bespoke software designed by Bonfire Technologies, Nepal. All
data were double entered; 10% of all entries were subjected to random inspection by a team of
dedicated data entry personnel from the Nepal Family Development Foundation (NFDF).
These were the source data for this study.
Microbiology procedures and statistical analysis
Conventional manual blood cultures were performed for the majority of the data used in these
analyses with the exception of the paediatric population (<14 years of age). Conventional
blood cultures were performed by inoculating 3–5 ml of blood from paediatric patients and
5–8 ml of blood from adult patients into 30–50 ml of media containing tryptone soya broth
containing 0.05% sodium polyanetholesulfonate. BACTEC Peds plus bottles (Becton
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Dickinson, Sparks, MD, USA) were used for the paediatric samples after an automated system
was introduced. Conventional bottles were incubated at 37˚C in a standard microbiological
incubator and examined daily for growth for a period of seven days. An automated BACTEC
(Becton Dickinson, MD, USA) culture system was used for paediatric samples from 2005
onwards. Organisms isolated from blood were identified using Gram staining, standard bio-
chemical tests, and specific antisera.
Antimicrobial susceptibilities were tested at the time of isolation by the modified Kirby-
Bauer disc diffusion method. Zone size interpretations were initially recorded according to the
guidelines provided in the antimicrobial packaging; from 2003 zone sizes were interpreted
according to the annual CLSI guidelines. Dependant on the period of isolation and the organ-
ism a range of antimicrobials were tested, including: Amikacin (AMK), amoxicillin (AMX),
ampicillin (AMP), cefixime (CFM), cefotaxime (CTX), ceftriaxone (CRO), cephalexin (LEX),
chloramphenicol (CHL), ciprofloxacin (CIP), trimethoprim-sulphamethoxazole (SXT), gati-
floxacin (GAT), gentamicin (GEN), nalidixic acid (NAL), norfloxacin (NOR), ofloxacin
(OFX), tetracycline (TET), tigecycline (TGC), tobramycin (TOB). Following antimicrobials
were occasionally tested for: ampicillin-sulbactam (SAM), cefepime-tazobactam (FEP.TZB),
cefoperazone (CFP), cefoperazone-sulbactam (CFP.SUL), cefoxitin (FOX), ceftriaxone-sulbac-
tam (CRO.SUL), cloxacillin (CLO), colistin (CST), erythromycin (ERY), imipenem (IPM),
meropenem (MEM), nitrofurantoin (NIT), oxacillin (OXA), penicillin (PEN), piperacillin
(PIP), piperacillin-tazobactam (TZP), and teicoplanin (TEC). Resistant and intermediate iso-
lates were grouped as “non-susceptible” and MDR was defined as non-susceptibility to ampi-
cillin/amoxicillin, chloramphenicol, and co-trimoxazole.
All statistical analysis was performed using statistical software R, version 3.3.2[9]. Increas-
ing or decreasing trends over time were identified using the Cox and Stuart test for trends (R-
package “randtrends”). Davies’ test (R-package “segmented”) was used to detect a non-con-
stant regression parameter (i.e. change in the slope) in linear regressions.
Results
General characteristics
From April 1992 to December 2014, a total of 224,741 individual patient blood samples were
drawn for microbiological culture at this healthcare facility. Of these, 173,892 (77.4%) were
culture-negative, 10,496 (4.7%) were positive for non-Salmonella bacteria, and 20,496 (9.1%)
were contaminated or contained fungi (Table 1). The remaining 8.8% of samples were positive
for Salmonella enterica sub-species I, accounting for 65.4% (19,857/30,353) of all the bacteria
positive blood cultures. S. Typhi and S. Paratyphi A were the dominant serovars, constituting
68.5% (13,592/19,857) and 30.5% (6,057/19,857) of all isolated Salmonellae, respectively
(Table 2). S. Paratyphi A represented 99.44% of all S. Paratyphi (6,057/6,091). The annual
Table 1. Summary of blood culture results between April 1992 and December 2014.
Blood cultures (n = 224,741) Number Percentage of cultures
Culture negative 173,892 77.37
Contamination*/Fungus 20,496 9.12
Salmonella enterica 19,857 8.84
Culture positive for other bacteria 10,496 4.67
* Contaminants included Bacillus spp., Coagulase negative staphylococci (excluding those from neonates),
Micrococcus spp., Acinetobacter spp. and Diptheroids.
https://doi.org/10.1371/journal.pntd.0006051.t001
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distributions of Salmonella-positive, positive for non-Salmonella bacteria, and culture-nega-
tive/contaminated blood cultures are shown in S1 Fig.
Time trends in the isolation of Salmonella Typhi and Salmonella
Paratyphi
The annual distributions of Salmonella-positive blood cultures (in all bacteriologically positive
blood cultures) are shown in Fig 1. The proportion of Salmonella positive blood cultures did
not exhibit a uniformly increasing or decreasing trend throughout the study period. However,
we observed a peak of 2,590 positive cultures in 2002, a year of unusually high rainfall and
flooding in the Kathmandu Valley. Subsequently, the total number of Salmonella-positive
cultures decreased towards pre-2002 baseline numbers and the proportion of Salmonella-posi-
tive blood cultures (in all bacteria-positive cultures) exhibited a significant decreasing trend
from 2002 to 2014 (p = 0.016). During this 13-year period (2002–2014), the proportion of Sal-
monella in all bacteria positive blood cultures decreased by a mean of 2.4% (95% CI: 1.1–3.7)
per year (S2 Fig). Additionally, there was a significant decreasing trend in the absolute number
of blood cultures from which Salmonella were isolated during this corresponding period
(p = 0.016).
S. Typhi was markedly the more prevalent of the two Salmonella serovars over the period of
investigation (Fig 1). However, the proportion of S. Typhi (with respect to all isolated Salmo-
nella) exhibited a significant decreasing trend from 1992 to 2014 (p = 0.033), decreasing on
average by 0.81% a year (95% CI: 0.3–1.3). Conversely, the proportion of S. Paratyphi A (with
respect to all isolated Salmonella) exhibited a significant increasing trend over the same time
period (p = 0.033).
To better appreciate the population presenting at this healthcare facility with enteric fever,
we investigated from which department within the hospital the blood samples that were posi-
tive for Salmonella had originated (Fig 2). Almost half of the S. Typhi and S. Paratyphi positive
cultures (6,713/13,592; 49.4% and 3,298/6,091; 54.1%, respectively) originated from the outpa-
tient department. Notably, the proportion of S. Typhi and S. Paratyphi positive blood cultures
arising from the emergency department increased from the year 2000 onwards; the emergency
department continued to contribute a large proportion of Salmonella-positive blood samples
after this year.
Fig 3 shows the monthly time series for the Salmonella-positive cultures. June, July, August,
and September were the months when the majority of Salmonella were isolated from blood
cultures. The number of Salmonella-positive blood cultures (all S. enterica, S. Typhi, and S.
Paratyphi A) exhibited maximal autocorrelation 12 months apart, therefore confirming
Table 2. Summary of Salmonella positive blood cultures between April 1992 and December 2014.
Positive cultures (n = 30,353) Number Percentage of
S. enterica
Percentage of bacteria positive
Salmonella Typhi 13,592 68.45 44.78
Salmonella Paratyphi A 6,057 30.50 19.96
Salmonella Paratyphi B 27 0.14 0.09
Salmonella Paratyphi C 3 0.02 0.01
Salmonella Paratyphi spp. 4 0.02 0.01
Salmonella Typhimurium 4 0.02 0.01
Salmonella Enteritidis 4 0.02 0.01
Other Salmonella serovars 166 0.84 0.55
Total 19,857 100 65.42
https://doi.org/10.1371/journal.pntd.0006051.t002
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seasonality of Salmonella infections (S3 Fig). The time trends, which represent longer-term
fluctuations in the number of positive blood cultures (after filtering for seasonality and ran-
dom variation), exhibited major peaks for S. Typhi and S. Paratyphi in 2002, as well as smaller
confined peaks for S. Typhi in 2005, 2010, and 2013 and S. Paratyphi in 2010.
Antimicrobial susceptibility patterns of Salmonella Typhi and Salmonella
Paratyphi
Trends of the antimicrobial susceptibility profiles of the Salmonella isolated from blood
between 1992 and 2014 are shown in Fig 4. We observed a significant change in the suscepti-
bility patterns against various antimicrobials over the study period, including increasing non-
susceptibility against fluoroquinolones and increasing susceptibility against ampicillin and tet-
racycline for both S. Typhi and S. Paratyphi.
We next investigated changes in susceptibility over the entire study period for the current
first-line antimicrobials, ciprofloxacin, nalidixic acid (as a marker of reduced susceptibility
against fluoroquinolones), and cefotaxime. Segmented linear regression was exploited to
detect changes in regression slopes between the proportion of non-susceptible organisms and
time (Fig 5). A change in slope (or “breakpoint”) was interpreted as a shift in the rate of resis-
tance acquisition at a particular time point. Non-susceptibility against nalidixic acid was con-
sistently high for S. Typhi and S. Paratyphi from 2002 to 2014, although a change in slope was
observed for ciprofloxacin non-susceptibility between 2010 and 2011 for S. Typhi, and between
2009 and 2010 for S. Paratyphi. These breakpoints demarcated period when ciprofloxacin
non-susceptibility remained low and constant and a sustained increase in ciprofloxacin non-
susceptibility. For cefotaxime, a decrease in the proportion of non-susceptible S. Typhi was
observed from 1993 to 1994, this was followed by a period of low and constant non-susceptibil-
ity from 1996 to 2014. For S. Paratyphi, non-susceptibility to cefotaxime was low and remained
constant from 1995 to 2014
We lastly examined the proportion of MDR organisms through time (Fig 5). We observed a
significant decrease in the proportion of MDR S. Typhi and S. Paratyphi from 1992 to 1997
and from 1992 to 1995, respectively. This period was followed by a period of low MDR preva-
lence, which was maintained throughout the study period. Notably, in 2002, a year with an
atypically high number of Salmonella isolations, the proportion of MDR S. Typhi was irregu-
larly high (19.7%), while the proportion of MDR S. Paratyphi isolates remained consistently
low (1.0%).
Discussion
Our study describes changes in the epidemiology and antimicrobial susceptibility patterns of
Salmonella isolated in a Kathmandu healthcare facility from 1992 to 2014. We document (i) a
significant decline in the number of Salmonella-positive cultures from 2002 (a year of heavy
rainfall and flooding in the Kathmandu Valley) to 2014, (ii) an increase in the proportion of S.
Paratyphi in all Salmonella-positive cultures between 1992 and 2014, (iii) a decline in MDR S.
Typhi and S. Paratyphi, and (iv) the recent increase in fluoroquinolone non-susceptibility in
both S. Typhi and S. Paratyphi.
Fig 1. The annual distribution of bacteria positive blood cultures from 1992 to 2014. Bar graph showing the annual counts (A)
and percentages (B) of Salmonella-positive cultures in all positive blood samples collected from 1992 to 2014. The annual
counts and percentages of S. Typhi, S. Paratyphi, and Salmonella spp. in all Salmonella-positive cultures collected from 1992 to
2014 are shown in (C) and (D), respectively.
https://doi.org/10.1371/journal.pntd.0006051.g001
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Fig 2. The annual distribution of ward from which Salmonella positive blood cultures were taken from 1992 to 2014. Annual
counts (A) and percentages (B) of the ward of origin for S. Typhi positive cultures collected from 1992 to 2014. The annual
counts and percentages of the ward of origin for the S. Paratyphi positive cultures collected from 1992 to 2014 are shown in
(C) and (D), respectively.
https://doi.org/10.1371/journal.pntd.0006051.g002
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In this comprehensive retrospective analysis of nearly 20,000 Salmonella-positive blood cul-
tures we report that overall prevalence of Salmonella isolation from blood cultures was 8.8%.
These data are consistent with data (7.2% and 13.4%) recently reported in other studies from
Nepal (10,11). Over the 23-year study period, S. Typhi and S. Paratyphi A represented almost
all Salmonella-positive cultures. However, their proportions varied over time: the proportion
of S. Typhi ranged from >80% in 1992 to<60% in 2014. These data are consistent with studies
citing a prevalence of 65.1% for S. Typhi and 34.9% for S. Paratyphi A in Alka Hospital, a
neighbouring Kathmandu hospital [10]. A prevalence of 57.8% for S. Typhi and 42.3% for S.
Paratyphi A was reported in a tertiary hospital in Kathmandu in 2012–2013 [11]. From 1992
to 2014, we observed a decreasing trend in the proportion of S. Typhi in all Salmonella-positive
cultures; this decrease was concurrent with an increasing in the proportion of S. Paratyphi iso-
lated. Similar increase have been reported in China [12] and Cambodia [13] and has been sug-
gested to be a major shift in the aetiology of enteric fever in Asia [8,14]. The precise
mechanism for this potential serovar replacement is unknown, but may be dependent on vari-
ous environmental, ecological, or epidemiological factors [14]. Additionally, S. Paratyphi A
does not harbour the Vi- polysaccharide capsule antigen, which is the key antigen used in all
available S. Typhi vaccines in Nepal. We have only limited data on the uptake of Vi vaccine in
this location, but a large Vi vaccine study was conducted in 2012 in all school-age children
[15]. This program likely had a major impact on S. Typhi incidence and the apparent propor-
tional increase in S. Paratyphi A cases. However, the vaccination program cannot entirely
explain the proportional increase of S. Paratyphi A, which seems to have started before 2012.
The study period was not characterized by a uniform decline in Salmonella, but rather by a
major peak in Salmonella-positive cultures in 2002. From 2002 to 2014, the absolute number
of both S. Typhi and S. Paratyphi positive cultures declined. It is unclear whether the observed
decline in S. enterica isolation from 2002 to 2014 was a return to baseline after a year of excep-
tionally high incidence in 2002, or if it reflected a true decrease in Salmonella incidence. High
numbers of S. enterica-positive blood cultures were also reported from nearby hospitals in
2002. From May to July 2002, a large single-point source outbreak of MDR S. Typhi associated
with the water supply system was reported in Bharatpur, a city ~100 km southwest of Kath-
mandu, with almost 6,000 confirmed or suspected cases [16]. This spike in Salmonella infec-
tions is likely associated with exceptional rainfall in Nepal that year, resulting in severe
flooding in the Kathmandu Valley in July. We have previously shown an association between
rainfall and an ability to detect S. Typhi and S. Paratyphi A DNA in the local water supplies
[17]. The major Salmonella outbreak in the middle of the study period is a reminder that the
Kathmandu Valley retains an epidemic potential for enteric fever. While we describe a
decrease in Salmonella incidence since 2002, the residual enteric fever burden may flare up
and cause large outbreaks under conducive conditions.
Our data additionally documented a decrease in the percentage of MDR Salmonella isolates;
this was observed for both S. Typhi (1992 to 1997) and S. Paratyphi (1992 to 1995). Other
researchers have suggested a decline in MDR-Salmonella in Nepal by showing that the major-
ity of Salmonella isolated between 2011 and 2013 were susceptible to chloramphenicol, ampi-
cillin, and co-trimoxazole [10,11]. Our longitudinal study confirms and expands these
findings by presenting detailed kinetics in MDR Salmonella trends over the last 23 years: a
decrease in the 1990’s followed by a long period of exceptionally low MDR prevalence.
Fig 3. Time series for Salmonella-positive cultures from 1992 to 2014. Plots showing the monthly time series
of all Salmonella positive blood cultures (absolute numbers in (A) and trends in (B)) between April 1992 and
December 2014. Time series (absolute numbers and trends) for S. Typhi are shown in (C) and (D), and for S.
Paratyphi in (E) and (F).
https://doi.org/10.1371/journal.pntd.0006051.g003
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Nalidixic acid resistance was found to be high for both S. Typhi and S. Paratyphi from 2003,
the same year when antimicrobial susceptibility testing began to be performed routinely. Resis-
tance to nalidixic acid is associated with a decline in fluoroquinolone susceptibility and the
imminent emergence of fluoroquinolone resistance[18]. Indeed, we report a dramatic increase
in ciprofloxacin non-susceptibility in both S. Typhi and S. Paratyphi from 2009, approaching
100% non-susceptibility by 2014. A gradual increase in ciprofloxacin non-susceptibility has
been implied by various studies reporting ciprofloxacin-resistance (or non-susceptibility) for
Salmonella in Nepal over the relevant years, ranging from 0% (S. Typhi) and 0.4% (S. Paratyphi
A) non-susceptibility in 1993–1998[5], 5% (S. Typhi) and 13% (S. Paratyphi A) non-suscepti-
bility in 1999–2003 [5], 2.8% (S. Typhi) and 10% (S. Paratyphi A) intermediate resistance in
2006–2007 [19], 8.4% resistance in 2010 [20], 0% (S. Typhi) and 3.3% (S. Paratyphi A) resis-
tance in 2011–2012 [10], and 83.1% non-susceptibility (resistant or intermediate) in 2012–
2013 [11]. Furthermore, an increase in ciprofloxacin minimal inhibitory concentrations
(MIC) was reported for S. Typhi between 2005 and 2014, with a sharp increase in 2009 [21].
Therefore, our data confirms this trend of increasing ciprofloxacin non-susceptibility in S.
Typhi and S. Paratyphi A, and details the kinetics of this transition over time. Notably, resis-
tance to the third generation cephalosporins was low throughout the whole study period for
both S. Typhi and S. Paratyphi A. Ceftriaxone remains the empirical antimicrobial of choice in
this setting, which we have shown to be efficacious in those with culture confirmed enteric
fever [22].
Though azithromycin is increasingly being used for the treatment of uncomplicated enteric
fever, the drug was not used within the Patan Hospital treatment regimens until 2006. Within
Patan Hospital it was rarely used for the treatment of enteric fever until 2014, when it was used
as a “rescue drug” when the other antimicrobials failed. Due to the unavailability of break
points for azithromycin against Salmonella, the microbiology laboratory did not perform any
susceptibility tests until 2015. We are therefore unable to make any conclusions on how azi-
thromycin resistance has evolved for Salmonella within our population. However, as of 2015,
after the introduction of breakpoints for azithromycin on Salmonella by the CLSI, the hospital
performs susceptibility testing and an ongoing surveillance monitors the MIC values.
The fluctuations in AMR profiles described in this study largely reflect changes in clinical
practices. MDR decreased as empirical treatment shifted from the fist-line antimicrobials
ampicillin, chloramphenicol, or co-trimoxazole to ciprofloxacin in the 1990s. As the MDR
phenotype is generally acquired via IncH1 resistance plasmids in S. Typhi [23,24], the reduc-
tion of selective pressure after cessation of chloramphenicol, ampicillin and/or co-trimoxazole
seems to induce the loss of these resistance plasmids and a reversion to a non-MDR pheno-
type. Subsequently, the routine use of ciprofloxacin to treat febrile diseases of presumed bacte-
rial origin was likely associated with the dramatic increase in ciprofloxacin-non-susceptibility
observed since 2009–2010. Recently, co-trimoxazole has been successfully used to treat a fluo-
roquinolone-resistant S. Typhi infection in Nepal, opening the debate about the re-deployment
of first-line antimicrobials [25]. Whilst currently efficacious against fluoroquinolone resistant
organisms, including the H58 variant, there is an obvious risk of re-emergence of resistance
with the reintroduction of the older antimicrobials, therefore methods such as antimicrobial
cycling could be considered [21].
Fig 4. The antimicrobial susceptibility profiles of isolated Salmonella from 1992 to 2014. Plots summarising antimicrobial
susceptibility data for all Salmonella (A), S. Typhi only (B), and S. Paratyphi only (C) from 1992 to 2014. The colour range on the
heat map tiles indicate the proportion of non-susceptible isolates (blue, low; red; high), the number of isolates tested is indicated on
the respective tile. Tiles with fewer than 10 isolates tested for the respective antimicrobial are not shown.
https://doi.org/10.1371/journal.pntd.0006051.g004
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Our findings from almost 20,000 Salmonella enterica isolates highlight the need to review
the current treatment protocols of enteric fever from fluoroquinolones as recommended by
the WHO and local health ministries. There is sufficient evidence to use azithromycin or ceph-
alosporins as the first antimicrobial therapy instead of fluoroquinolones [22,26]. With the re-
emergence of efficacy in older antimicrobials used to treat enteric fever, they could be consid-
ered for use, but perhaps in combination with other antimicrobials to avoid an early re-emer-
gence of resistance to these antimicrobials. However, treatment guidelines should be
meticulously guided by microbiology data.
Our analysis though comprehensive has a few limitations, being a passive surveillance
focused on one particular hospital. One of our primary limitations is the use of different sus-
ceptibility guidelines used for resistance interpretation over time as the CLSI guidelines were
unavailable locally prior to 2003. We were not able to provide a consistent interpretation
through the retrospective use of CLSI guidelines as the isolates were not stored and the disc
diameters were not recorded. Another limitation is the population that is seen in the hospital,
though the catchment area of the hospital has remained the same throughout the study period,
many other health care facilities have opened up over time within this area where a certain
subset population would go to seek medical care. However, Patan Hospital, being the biggest
general hospital in the area still does see a majority of the patients within the catchment area.
Hospital records showing individuals seeking care in Patan Hospital has increased consistently
over the years, in accordance to the increase of the local population.
Supporting information
S1 Fig. The annual distribution of blood culture results. Annual counts (A) and percentages
(B) of Salmonella-positive cultures, cultures positive for other bacteria, negative cultures and
contamination in all blood cultures taken between 1992 and 2014.
(EPS)
S2 Fig. The annual distribution of Salmonella-positive cultures. Percentage of Salmonella-
positive cultures among all positive cultures from 1992 to 2014. Symbol size is proportional to
the number of positive cultures. A linear regression trend-line (blue) and confidence interval
(shaded) are overlaid from 2002 to 2014 to illustrate the decline in the proportion of Salmo-
nella in all positive cultures. The slope (and 95% CI) of the regression line is indicated on the
graph.
(EPS)
S3 Fig. Autocorrelation function of Salmonella cases. Autocorrelation function (ACF) for
monthly time series for Salmonella (Tyhi, Paratyphi and spp) (A), S. Typhi (B) and S. Paratyphi
(C). One lag represents one year divided in 12 months.
(EPS)
S1 Data. Microbiology laboratory report on Salmonella spp from April 1992 to December
2014 from Patan Hospital.
(CSV)
Fig 5. The development of non-susceptibility against selected antimicrobials and multidrug resistance. Plots showing changes in non-susceptibility against i)
nalidixic acid for S. Typhi (A) and S. Paratyphi A (B), ii) against ciprofloxacin for S. Typhi (C) and S. Paratyphi (D), iii) against cefotaxime for S. Typhi (E) and
S. Paratyphi A (F), and iv) multidrug resistance for S. Typhi (G) and S. Paratyphi (H) between 1992 and 2014. The linear trend-lines (blue) and 95% CI for the
regression lines (shaded) are overlaid on the data points. The slope of the regression line (with 95% CI) is indicated on each plot; two regression lines are
present when a breakpoint in the slope was detected.
https://doi.org/10.1371/journal.pntd.0006051.g005
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